A randomized, Phase I, single-center, observer-blind, active-controlled study to evaluate the safety, tolerability and immunogenicity of one single administration of PCV-LITE, a novel adjuvanted pneumococcal conjugate vaccine at one dose level of LiteVax Adjuvant, in healthy participants aged 18-50 years.

Authors
Category Primary study
Registry of TrialsClinical Trials Information System
Year 2024
This article has no abstract
Epistemonikos ID: a1e2989381ef56bfba1fc87bd63efd2410cff5de
First added on: Mar 21, 2025